Diabetes

The FDA has cleared the Nova StatStrip Glucose Hospital Meter System to become the first blood glucose monitoring system for use in critically ill patients who have been hospitalized.

Combined with bolus insulin aspart (NovoLog), insulin degludec (Tresiba) improves long-term glycemic control in children and adolescents with type 1 diabetes.

The FDA today approved dulaglutide (Trulicity), a once-weekly injectable therapy indicated to improve blood sugar control in adults with type 2 diabetes.

Results show pharmacists and other healthcare providers can work together to successfully empower patients disproportionately affected by diabetes to achieve improved clinical outcomes.

The risk for developing prediabetes was doubled among hypertensive patients who drank more than 3 cups of coffee per day.

Extended-release naltrexone hydrochloride and bupropion hydrochloride (Contrave) has been approved as an adjunct therapy for chronic weight management in obese adults.

The prevalence of type 2 diabetes mellitus (T2DM) in the United States has been rising for decades. A new study suggests that body mass index is the largest contributor to the rising rate of T2DM.

AstraZeneca's injectable medication to improve glycemic control among adults with type 2 diabetes is now widely available across US pharmacies.

Learn the fascinating details of the discovery of incretin-active agents, including DPP4 inhibitors, GLP-1 agonists, and GLP-2 agonists.

New blood glucose monitoring system transfers data to iOS devices using the headphone jack, rather than an adaptor or other technology.

The NephroCheck test detects levels of 2 AKI markers, which can determine whether the condition will progress to moderate or severe injury.

A model used in 3 studies was found to accurately predict serious complications in patients with type 1 diabetes.

Children and adolescents who received antipsychotic medications had an increased absolute risk of developing type 2 diabetes.

Adolescents exposed to gestational diabetes in utero have a higher risk of developing impaired glucose tolerance.

The FDA has approved the first zinc transporter 8 autoantibody test that may help patients with type 1 diabetes mellitus receive more timely diagnosis and treatment for the disease.

A new drug was recently given tentative approval by the FDA to help patients with both type 1 and type 2 diabetes.

A patient's lifetime risk of developing type 2 diabetes currently stands at 40%, with an even higher risk for some ethnic groups.

Jesse McCullough, PharmD, director of field clinical services for Rite Aid, discusses the implications of a pharmacist-led intervention to boost medication adherence.

Community pharmacists dramatically boost medication adherence among patients with chronic conditions.

In a recent study, patients with diabetes who were referred to a pharmacist-led clinic by their primary care providers saw their mean HbA1C levels fall by 2.4%.

American adults are eating too little fish to meet current recommendations for fish-derived omega-3 fatty acids.

Moderate intake of long chain omega-3 polyunsaturated fatty acids as a lipid-lowering strategy appears to have no effects on glucose regulation or insulin resistance.

Researchers in Taiwan have found an increased risk for head and neck cancers among patients with diabetes mellitus.